FSD Pharma (FSD Pharma) Interest Expense : $-0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. FSD Pharma's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. FSD Pharma's Operating Income for the three months ended in Dec. 2023 was $ -1.90 Mil. FSD Pharma's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. FSD Pharma has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

FSD Pharma Interest Expense Historical Data

The historical data trend for FSD Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Interest Expense Chart

FSD Pharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.16

-0.24

-0.07

-0.05

FSD Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

FSD Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

FSD Pharma (NAS:HUGE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

FSD Pharma's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-1.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

FSD Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

FSD Pharma had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

FSD Pharma (FSD Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

0K9:Germany HUGE:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.